All News
The Need for Comparative Treatment Trials in Psoriatic Arthritis
Psoriatic arthritis is currently experiencing a burgeoning selection of treatment options. While this is a very welcome development in a disease which has had less treatment options compared to RA, it leaves us with a difficult conundrum: which agent to choose for an individual patient.
Read Article
Breakthrough COVID-19 in rheum pts: great data @rheum_covid
B-cell depleting agents overrepresented, esp in hospitalization in fully vaccinated - but plenty of others
Booster (& booster booster) vaccine doses + other mitigation badly needed!
@rheum_cat #ACR21 ABSTL04 @RheumNow https://t.co/92Sn3mCwAi
David Liew drdavidliew ( View Tweet)
#Depression is associated with a 3x increased mortality risk in patients with incident #RA.
👉🏼Results from #DANBIO
👉🏼~11000 RA pts, ~1000 starting antidepressants
Abs#1659 #ACR21 @RheumNow
https://t.co/SsEjmLzacP https://t.co/1GiFE0KLjK
Mrinalini Dey DrMiniDey ( View Tweet)
Individual patient data analysis from RCTs (indirect comparison) of guselkumab vs ustekinumab in PsA. Guselkumab appears superior for joint and skin. Abstr#1773 #ACR21 @RheumNow https://t.co/MTRjXyHoh6
Richard Conway RichardPAConway ( View Tweet)
#ACR21 L04 @rheumcat on #COVID19 in vaxed pts
▶️87 pts in @rheum_covid w/ ifn s/p full vax. 110 partial vax pts
⭐️25% (22/87) full vax pts hospitalized. 45% on BCDT. 8/22 hospitalized had lung disease, 5 no other co-morbidities. 5 deaths (23%).
@RheumNow https://t.co/DB8C6jKvuU https://t.co/dxUwjTRxxb
Links:
Eric Dein ericdeinmd ( View Tweet)
You need to visit this nonprofit on the #ACR21 website and also their website https://t.co/8SrCHZUrk0
to help patients & doctors navigate getting the meds pts need. There are resources explaining step therapy and how to navigate access restrictions for patients. @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
No significant difference in enthesitis activity in PsA pts taking csDMARD vs. TNFi vs. IL-17i
⭐️Age, duration of disease, physician global were main differences in TNFi and IL-17i vs. cDMARD
⭐️no specific clustering noted
Abs#1782
#ACR21 @RheumNow
https://t.co/AH33ZjHUa1 https://t.co/Gb2zKMBUqo
Links:
Robert B Chao, MD doctorRBC ( View Tweet)
Dr Kwok on isolated axial disease in PsA. Seen in 2% of cohort. Significantly more likely to be HLA-B27 positive. Lower HAQ score. No obvious predictors of future development of peripheral disease. Abstr#1775 #ACR21 @RheumNow https://t.co/SqpaLjCrmm
Richard Conway RichardPAConway ( View Tweet)
#ACR21 L05. Tigulixostat - non-purine selective XO inhibitor for gout
⭐️Effectively brought down serum uric acid <5, dose-dependent
⭐️10% pts gout flare with urate lowering
@Rheumnow https://t.co/LgwkAQ1wg8 https://t.co/G8CxdGcVOQ
Links:
Eric Dein ericdeinmd ( View Tweet)
Minority (African American and Hispanic) #SLE patients have worse #COVID19 outcomes – double whammy! Data from the @rheum_covid #ACR21 @rheumnow #abst1933
Bella Mehta bella_mehta ( View Tweet)
#ACR21 L07 - Rx for IBM?!
⭐️Depletion of KLRG1+ T cells - trial of ABC008
⭐️Presented data from 3 patients in 1st human studies
▶️single SC 0.1 mg/kg dose depletes CD8+KLRG1+ cells wo safety concerns
@Rheumnow https://t.co/1J8PrOqbWh
Links:
Eric Dein ericdeinmd ( View Tweet)
I remember, not that long ago, inclusion body myositis evoked resignation, for pts & clinicians. A bizarre condition where standard of care was counselling/mitigation
Now there hope might be on the horizon
Exciting to see the science & a feasible target
#ACR21 ABSTL07 @RheumNow https://t.co/CYiAXIEA0Q
David Liew drdavidliew ( View Tweet)
Phase 2 Placebo/Deucravacitinib 6mg/12mg od study ACR20 at 16 weeks of 31.8%/52.9%/62.7% respectively. Efficacy observed across TNFi and body weight subgroups. Safety profile similar to Phase 3 trials in patients with psoriasis @RheumNow #ACR21 Abst#1820 https://t.co/bOfEZdqN5Z https://t.co/EjMwWISM80
Dr. Antoni Chan synovialjoints ( View Tweet)
#SLE patients with limited health literacy affects vulnerable black patients in multiple domains – worse disease activity/damage, physician/patient communication, worse patient centered care, and patient activation @mithurheum #ACR21 @rheumnow #ACRBest abst#L08
Bella Mehta bella_mehta ( View Tweet)
To be clear, for IBM: resignation 'not that long ago' = yesterday. Early days I know, but nothing like a plausible, feasible target to bring hope
@UpToDate screenshot
exciting times at #ACR21 @RheumNow https://t.co/WAEUtQagym
David Liew drdavidliew ( View Tweet)
#ACR21 L10 TRAIL1: Pirfenidone for RA-ILD
⭐️Low pt enrollment due to pandemic, 1/2 of planned trial size
▶️ Unable to meet primary endpt (composite death+FVC) but met FVC markers. Most pronounced in UIP patterns on HRCT
@Rheumnow https://t.co/HB7N9Wl9Dn https://t.co/muBEguAAja
Links:
Eric Dein ericdeinmd ( View Tweet)
#Sleep disturbance is common in #RA but does it correlate with disease activity?
Results from >100 RA pts suggest yes.
Many reported sleep disturbances, associated with both incr patient & physician-assessed disease activity.
Abs#1666 #ACR21 @RheumNow
https://t.co/ud2uMf25cI https://t.co/BE4UHPB0f1
Mrinalini Dey DrMiniDey ( View Tweet)
RheumNow’s expanded coverage of the #ACR21 Annual meeting is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Predicting RA, and Treatment of Subclinical Arthritis
Dr. Meral K. El Ramahi ( @MeralElRamahiMD) shares the abstracts discussed at #ACR21 focusing on predicting RA and treating subclinical arthritis.
https://t.co/DYgV43JpgT https://t.co/U2NfXrfYZU
Links:
Dr. John Cush RheumNow ( View Tweet)
My article on the potential use of BMI to guide biologic selection in RA. Discussing #ACR21 abstract 0588 by @MilenaGianfran @JYazdanyMD https://t.co/hxliSZ3IBS @RheumNow
Richard Conway RichardPAConway ( View Tweet)